Colorectal Cancer Treatment in Hyderabad
Reviewed May 2026 · Updated August 2026 · Dr. Madhav Danthala
Colorectal cancer is the fastest-growing cancer in young adults in Indian metros. The screening age is 45, not 50. Dr. Madhav Danthala provides treatment planning, chemotherapy, targeted therapy, and immunotherapy at KIMS-Sunshine Hospitals, Begumpet, with evening consultations at Peoples Polyclinic, Manikonda.
When to See a Doctor
Most causes of these symptoms are benign — most rectal bleeding is haemorrhoids. The pattern that matters is when something is new, persistent, or accompanied by other warning signs.
- Blood in stool — persistent or recurrent, especially after age 45.
- Bowel habit change — new constipation, diarrhoea, or incomplete emptying.
- Unexplained weight loss — more than 5 kg lost without change in diet or activity.
- Iron-deficiency anaemia — unexplained low haemoglobin — prompt colonoscopy in adults.
Dr. Danthala's Approach
Colorectal cancer treatment in 2026 is increasingly molecularly guided. Three principles shape every consultation.
-
Molecular profiling first
MSI status, KRAS, NRAS, BRAF, and HER2 are tested at diagnosis to guide therapy choice and identify candidates for immunotherapy.
-
More than one path
For rectal cancer, total neoadjuvant therapy and watch-and-wait protocols are increasingly defensible alternatives to immediate surgery in selected patients. See First, Do Not Cut and the Sukhibhava TV segment on chemotherapy before surgery.
-
Clear, structured communication
Every consult ends with a written summary of options, expected timelines, and the trade-offs each plan carries.
Treatment Options
Colorectal cancer treatment depends on three things: stage, location (colon vs rectum), and molecular profile (MSI, KRAS, BRAF, HER2). Below are the major modalities patients should expect to see in a treatment plan.
Hemicolectomy, low anterior resection, total mesorectal excision
For colon cancer, the standard surgery is right or left hemicolectomy with regional lymphadenectomy. Rectal cancer requires total mesorectal excision (TME), often with low anterior resection or, less commonly, abdominoperineal resection. Laparoscopic and robotic approaches are routine and reduce recovery time. Sphincter-preserving surgery is the goal whenever oncologically safe.
FOLFOX, CAPOX adjuvant — FOLFIRI for advanced disease
Stage III colon cancer benefits from adjuvant chemotherapy with FOLFOX or CAPOX (3 to 6 months, often 3 months for low-risk per IDEA trial). For metastatic disease, FOLFIRI or FOLFOX combined with biologics is standard. Triplet regimens (FOLFOXIRI) are reserved for fit patients with high tumour burden.
Anti-EGFR, anti-VEGF, anti-HER2, BRAF combinations
Cetuximab and panitumumab (anti-EGFR) are options for KRAS/NRAS/BRAF wild-type left-sided tumours. Bevacizumab (anti-VEGF) adds benefit across most regimens. BRAF V600E mutations are treated with encorafenib + cetuximab. HER2-amplified disease responds to trastuzumab + tucatinib. Molecular profiling at diagnosis is essential to identify these options.
Pembrolizumab for MSI-high; chemoradiation for rectal
For MSI-high (~15% of colorectal cancers), pembrolizumab is now first-line for advanced disease (KEYNOTE-177) and increasingly used in early-stage as neoadjuvant therapy with remarkable response rates. For rectal cancer, total neoadjuvant therapy (chemo + chemoradiation before surgery) and watch-and-wait protocols for complete clinical responders are emerging as alternatives to immediate surgery.
Treatment is shaped by stage, location, molecular profile, and patient preference. The list above is the menu. The right plan is built with the patient in the room.
From Colonoscopy to First Cycle
Colon and rectal cancers separate early — usually within the first fortnight, and usually on the strength of one scan. What follows is the workup a colorectal cancer should get in Hyderabad before anyone commits to an operation.
A complete colonoscopy, and a baseline CEA
Biopsy confirms the diagnosis; a complete colonoscopy matters because synchronous second tumours occur in a small but real fraction of patients and are far better found before surgery than after. If the tumour is obstructing and the scope cannot pass, CT colonography now — or a completion scope after treatment — closes that gap. A baseline CEA is drawn here so later values mean something.
For rectal cancer, the pelvic MRI decides the plan
Colon cancer is staged with a CT of the chest, abdomen and pelvis. Rectal cancer needs a high-resolution pelvic MRI as well, and it is not optional: it defines the circumferential resection margin, the mesorectal nodes and the sphincter relationship — which together decide whether chemoradiation or chemotherapy should come before surgery. A rectal cancer operated on without a staging MRI has had its most important decision made by default.
MMR/MSI on every tumour — RAS, BRAF and HER2 on metastatic disease
Mismatch-repair status by immunohistochemistry (or MSI by PCR) belongs on every colorectal cancer, not only advanced ones: it flags Lynch syndrome for the whole family and identifies the roughly 15% of tumours that respond exceptionally to immunotherapy. For metastatic disease, add RAS, BRAF V600E and HER2 — these decide whether anti-EGFR therapy is useful or actively pointless.
Surgery first, or not first
For most colon cancers, surgery leads and chemotherapy follows by stage. For locally advanced rectal cancer, total neoadjuvant therapy — chemotherapy and chemoradiation completed before the operation — has become the standard approach, and a minority of complete responders can be offered organ preservation with close surveillance instead of resection. Operating first can close that door permanently. Dr. Danthala explains the case for treating before cutting on ETV Sukhibhava and in the essay First, Do Not Cut.
Port, stoma conversation, first cycle
If chemotherapy is starting, a port is placed and the regimen — FOLFOX, CAPOX or a biologic combination — is set against stage and molecular profile. If a temporary stoma is likely, that conversation belongs here rather than on the day before surgery: stoma siting, care, and the expected timeline to reversal are all easier to absorb in advance.
Young-onset colorectal cancer is now the fastest-growing presentation in Indian metros, and the screening age moved to 45 for that reason — see why colonoscopy now starts at 45. Rectal bleeding attributed to piles for six months in someone under 50 is the single most common avoidable delay.
Frequently Asked Questions
At what age should I start colonoscopy screening in India?
The recommended screening age was lowered from 50 to 45 in 2021 and has been adopted globally including in India. Young-onset colorectal cancer (under 50) is now the fastest-growing cancer in some Indian metros.
Does blood in stool always mean cancer?
No. The most common cause is haemorrhoids. However, persistent or recurrent blood — especially in anyone over 45, or with changes in bowel habits, weight loss, or anaemia — should be evaluated promptly.
What is MSI-high colon cancer?
MSI-high describes a tumour with defective DNA-repair machinery. About 15% of colon cancers are MSI-high. These respond exceptionally well to immunotherapy. MSI status should be tested in all colorectal cancers at diagnosis.
When should I start screening earlier than 45?
If a first-degree relative had colorectal cancer (start at 40 or 10 years before their diagnosis), with inflammatory bowel disease, previous adenomatous polyps, or hereditary syndromes like Lynch syndrome. Lynch syndrome also raises lifetime risk of ovarian, stomach, and endometrial cancers — genetic counselling guides surveillance across all of them, not just the bowel.
What does treatment usually involve?
Early-stage colon cancer: surgery, sometimes followed by chemotherapy. Rectal cancer: often combined chemoradiation followed by surgery. Advanced disease: chemotherapy plus targeted therapy or immunotherapy depending on molecular profile.
Where can I consult Dr. Madhav Danthala for colorectal cancer in Hyderabad?
Dr. Madhav Danthala consults at KIMS-Sunshine Hospitals, Begumpet (Room 545, 5th Floor OPD, Prakash Nagar 500003; Mon–Sat, 9 AM to 5 PM) and at Peoples Polyclinic, Manikonda (1st Floor, Sree Srinivasam Building 500089; Mon–Sat, 6 PM to 8 PM, prior appointment only). Begumpet appointments are booked online via KIMS Hospitals or KIMS Sunshine. For Manikonda evenings call Naresh on +91 80089 83828, or request a callback.
Is chemotherapy given before surgery for rectal cancer?
Often, yes. For locally advanced rectal cancer, total neoadjuvant therapy — chemotherapy and chemoradiation completed before the operation — has become the standard approach. It improves local control, increases the chance of sphincter-preserving surgery, and identifies the minority of patients whose tumour disappears completely on treatment, who can then be offered close surveillance instead of resection. Operating first forfeits that option. Dr. Madhav Danthala explains chemotherapy before surgery on ETV Sukhibhava.
What is total neoadjuvant therapy (TNT) and watch-and-wait?
Total neoadjuvant therapy delivers the full course of chemotherapy and chemoradiation before surgery rather than splitting it around the operation. In a subset of rectal cancers the tumour achieves a complete clinical response — nothing detectable on endoscopy, digital examination or MRI — and those patients may be offered organ preservation, or watch-and-wait: no resection, but an intensive surveillance schedule for several years with salvage surgery if the tumour regrows. It is a genuine option for selected patients, not a way of avoiding treatment, and it depends on disciplined follow-up.
Why is colorectal cancer rising in people under 50 in India?
Young-onset colorectal cancer is the fastest-growing presentation in Indian metros, and the drivers appear to be a mix of dietary shift, sedentary work, obesity, and changes in the gut microbiome — with a minority explained by hereditary syndromes such as Lynch syndrome. The practical consequence is that rectal bleeding in a person under 50 should not be attributed to haemorrhoids for months without examination. Screening now begins at 45 for average risk, and earlier with family history — see why colonoscopy now starts at 45.
How long does colorectal cancer treatment take?
For stage III colon cancer, expect surgery followed by three to six months of adjuvant chemotherapy, with the shorter duration appropriate for lower-risk disease. Locally advanced rectal cancer treated with total neoadjuvant therapy typically runs four to six months of treatment before surgery, then recovery, and a temporary stoma is often reversed a few months later. Metastatic disease is managed continuously rather than in a fixed course, with treatment adjusted at each scan.
About Dr. Madhav Danthala
Trusted guidelines & further reading
- ESMO — Cancer Guides for Patients European Society for Medical Oncology patient guides — freely accessible, evidence-based.
- ASCO / Cancer.Net — Colorectal Cancer American Society of Clinical Oncology patient education portal.
- NCI / Cancer.gov — Colorectal Cancer US National Cancer Institute clinical treatment summaries.
On television & podcast
- Chemotherapy Before Surgery — Neoadjuvant Therapy | Sukhibhava (ETV) Neoadjuvant treatment in rectal, gastric and oesophageal cancer, and when organ preservation becomes possible.
- Why Cancer Is Still Diagnosed Late — Vanitha TV The delay pattern behind young-onset colorectal cancer: bleeding attributed to piles for months.
- Screening After 40 — Vanitha TV Which screening tests are worth doing, and at what age, for average-risk adults.
From our blog
- Why Colonoscopy Now Starts at 45, Not 50 The screening age moved for a reason. Who should start even earlier, and why colonoscopy still beats FIT for prevention.
- Your Mother's Medical History Is Your Screening Map Lynch syndrome connects colorectal cancer to ovarian and gastric — the right family question shifts the screening calendar by years.
- The Two-Oncologist Rule: When to Get a Second Opinion Rectal cancer (TNT vs. watch-and-wait) is one of the clearest cases for a second opinion in modern oncology.